Rhythm Pharmaceuticals has amended its exclusive license agreement with LG Chem for bivamelagon, an oral small-molecule ...
The biotech has raised $25 million to scale its human cell models, targeting industry-standard status as drug discovery ...
Anthropic wants to use AI to address common bottlenecks in clinical trials and says collaborations with B-MS and Enveda – as ...
GSK leader shares tips on how to always keep mature brand speaker programs relevant, credible and compliant over time.
Some have called this announcement a "yellow light" or "backdoor" approval of these gray-market peptides. However, the HHS ...
START and IFO launch a new early-phase cancer trial site in Rome, giving patients access to novel investigational treatments ...
Biopharma sponsors trialling drugs with medical devices can now seek authorization through the EU COMBINE pilot scheme, ...
BioMarin has agreed to pay $70 million upfront for Fabry disease therapy from GC Biopharma and Hanmi Pharm. At the center of ...
Brise Pharmaceuticals has revealed a licensing agreement with AbbVie for two preclinical migraine programs, with potential ...
A new biotech born from Jazz Pharmaceuticals' acquisition deal is betting that rare disease genetics can unlock treatments ...
The sale gives Lonza added US manufacturing capacity and extends its run of portfolio reshaping, while Merck KGaA sharpens ...
Hematology research now needs new evidence strategies as targeted therapies create smaller, more specialized patient groups ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results